Circulating Cell-Free DNA and Circulating Tumor Cells As Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2017 May 12

PMID 28492516

Citations 26

Authors

Simona Coco

Angela Alama

Irene Vanni

Vincenzo Fontana

Carlo Genova

Maria Giovanna Dal Bello

Anna Truini

Erika Rijavec

Federica Biello

Claudio Sini

Giovanni Burrafato

Claudia Maggioni

Giulia Barletta

Francesco Grossi

Affiliations

Soon will be listed here.

Abstract

Cell-free DNA (cfDNA) and circulating tumor cells (CTCs) are promising prognostic and predictive biomarkers in non-small cell lung cancer (NSCLC). In this study, we examined the prognostic role of cfDNA and CTCs, in separate and joint analyses, in NSCLC patients receiving first line chemotherapy. Seventy-three patients with advanced NSCLC were enrolled in this study. CfDNA and CTC were analyzed at baseline and after two cycles of chemotherapy. Plasma cfDNA quantification was performed by quantitative PCR (qPCR) whereas CTCs were isolated by the ScreenCell Cyto (ScreenCell, Paris, France) device and enumerated according to malignant features. Patients with baseline cfDNA higher than the median value (96.3 copy number) had a significantly worse overall survival (OS) and double the risk of death (hazard ratio (HR): 2.14; 95% confidence limits (CL) = 1.24-3.68; -value = 0.006). Conversely, an inverse relationship between CTC median baseline number (6 CTC/3 mL of blood) and OS was observed. In addition, we found that in patients reporting stable disease (SD), the baseline cfDNA and CTCs were able to discriminate patients at high risk of poor survival. cfDNA demonstrated a more reliable biomarker than CTCs in the overall population. In the subgroup of SD patients, both biomarkers identified patients at high risk of poor prognosis who might deserve additional/alternative therapeutic interventions.

Citing Articles

Establishing and Validating a novel Prognostic Model in the Initial Diagnosis of Non-small Cell Lung Cancer with Bone Metastases.

Li B, Su D, Wen X, Jia M, Xue N, Chen S J Cancer. 2024; 15(14):4612-4622.

PMID: 39006082 PMC: 11242352. DOI: 10.7150/jca.95784.

Ravi N, Gupta P, Bal A, Prasad K, Garg M, Kapoor R Explor Target Antitumor Ther. 2024; 5(3):508-521.

PMID: 38966173 PMC: 11222716. DOI: 10.37349/etat.2024.00232.

Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I-IIIA NSCLC.

Garitaonaindia Y, Aguado-Noya R, Garcia-Grande A, Cordoba M, Coronado Albi M, Campo Canaveral J Transl Lung Cancer Res. 2023; 12(7):1414-1424.

PMID: 37577300 PMC: 10413043. DOI: 10.21037/tlcr-22-827.

Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review.

Tomasik B, Skrzypski M, Bienkowski M, Dziadziuszko R, Jassem J Transl Lung Cancer Res. 2023; 12(3):594-614.

PMID: 37057121 PMC: 10087994. DOI: 10.21037/tlcr-22-742.

Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study.

Gristina V, Barraco N, La Mantia M, Castellana L, Insalaco L, Bono M Cancers (Basel). 2022; 14(23).

PMID: 36497493 PMC: 9735435. DOI: 10.3390/cancers14236013.

References

Moro-Sibilot D, Smit E, de Castro Carpeno J, Lesniewski-Kmak K, Aerts J, Villatoro R . Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study. Lung Cancer. 2015; 88(2):215-22. DOI: 10.1016/j.lungcan.2015.02.011. View

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

Krebs M, Hou J, Sloane R, Lancashire L, Priest L, Nonaka D . Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol. 2011; 7(2):306-15. DOI: 10.1097/JTO.0b013e31823c5c16. View

Vanni I, Alama A, Grossi F, Dal Bello M, Coco S . Exosomes: a new horizon in lung cancer. Drug Discov Today. 2017; 22(6):927-936. DOI: 10.1016/j.drudis.2017.03.004. View

Bulfoni M, Turetta M, Del Ben F, Di Loreto C, Beltrami A, Cesselli D . Dissecting the Heterogeneity of Circulating Tumor Cells in Metastatic Breast Cancer: Going Far Beyond the Needle in the Haystack. Int J Mol Sci. 2016; 17(10). PMC: 5085799. DOI: 10.3390/ijms17101775. View

Dowler Nygaard A, Spindler K, Pallisgaard N, Andersen R, Jakobsen A . Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC. Oncol Rep. 2013; 31(2):969-74. DOI: 10.3892/or.2013.2906. View

Cohen S, Punt C, Iannotti N, Saidman B, Sabbath K, Gabrail N . Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(19):3213-21. DOI: 10.1200/JCO.2007.15.8923. View

Goldstraw P, Crowley J, Chansky K, Giroux D, Groome P, Rami-Porta R . The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007; 2(8):706-14. DOI: 10.1097/JTO.0b013e31812f3c1a. View

Gold B, Cankovic M, Furtado L, Meier F, Gocke C . Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology. J Mol Diagn. 2015; 17(3):209-24. PMC: 4411248. DOI: 10.1016/j.jmoldx.2015.02.001. View

10.

Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chasse E . Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol. 2004; 22(20):4157-64. DOI: 10.1200/JCO.2004.11.123. View

11.

Sirera R, Bremnes R, Cabrera A, Jantus-Lewintre E, Sanmartin E, Blasco A . Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011; 6(2):286-90. DOI: 10.1097/JTO.0b013e31820189a5. View

12.

Freidin M, Tay A, Freydina D, Chudasama D, Nicholson A, Rice A . An assessment of diagnostic performance of a filter-based antibody-independent peripheral blood circulating tumour cell capture paired with cytomorphologic criteria for the diagnosis of cancer. Lung Cancer. 2014; 85(2):182-5. DOI: 10.1016/j.lungcan.2014.05.017. View

13.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

14.

Truini A, Alama A, Dal Bello M, Coco S, Vanni I, Rijavec E . Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System. Front Oncol. 2014; 4:242. PMC: 4154446. DOI: 10.3389/fonc.2014.00242. View

15.

Desitter I, Guerrouahen B, Benali-Furet N, Wechsler J, Janne P, Kuang Y . A new device for rapid isolation by size and characterization of rare circulating tumor cells. Anticancer Res. 2011; 31(2):427-41. View

16.

Fiammengo R . Can nanotechnology improve cancer diagnosis through miRNA detection?. Biomark Med. 2016; 11(1):69-86. DOI: 10.2217/bmm-2016-0195. View

17.

Li B, Drilon A, Johnson M, Hsu M, Sima C, Mcginn C . A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers. Ann Oncol. 2015; 27(1):154-9. PMC: 4684155. DOI: 10.1093/annonc/mdv498. View

18.

Alama A, Truini A, Coco S, Genova C, Grossi F . Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer. Drug Discov Today. 2014; 19(10):1671-6. DOI: 10.1016/j.drudis.2014.06.001. View

19.

Zhang Z, Xiao Y, Zhao J, Chen M, Xu Y, Zhong W . Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non-small-cell lung cancer. Respirology. 2015; 21(3):519-25. DOI: 10.1111/resp.12696. View

20.

Zhou J, Dong F, Cui F, Xu R, Tang X . The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2017; 79(4):825-833. DOI: 10.1007/s00280-017-3269-x. View